Email:
Phone:
Toggle navigation
Home
Services
ADC Linkers Development
Chemically Labile Linkers
Acid Cleavable Linkers/Hydrazone Linkers
Disulfide Linkers
Enzymatically Cleavable Linkers
Cathepsin B Cleavable Linkers/Peptide Linkers
Phosphatase Cleavable Linkers
Sulfatase Cleavable Linkers
β-Galactosidase Cleavable Linkers
β-Glucuronidases Cleavable Linkers
Non-cleavable Linkers
Antibody Modification and Conjugation Technologies
Bispecific Antibody Conjugation
Carbohydrate Conjugation
Cysteine Conjugation
Enzymatic Conjugation
Lysine Conjugation
Site-Specific Conjugation
Thio-engineered Antibody
Unnatural Amino Acids Conjugation
ADC Analysis and Characterization
ADC
In Vitro
Analysis
ADC
In Vivo
Analysis
ADC ADME Characterization
ADC DMPK Analysis
Bioanalytics
Bioassays
DAR and Drug Distribution Analysis
Stability Analysis Services
ADC Linker and Cytotoxin Conjugations
Calicheamicin-based Linker and Cytotoxin Conjugation
Deruxtecan-based Linker and Cytotoxin Conjugation
MMAE/MMAF-based Linker and Cytotoxin Conjugation
PBD-based Linker and Cytotoxin Conjugation
SN-38-based Linker and Cytotoxin Conjugation
ADC Payloads Development
Biological Payloads
Chemical Payloads
Protein Toxins
ADC Manufacture
ADC cGMP Manufacture
ADC Fill/Finish
ADC Purification
ADC Development for Targets
ADC Development for AXL Targets
ADC Development for BCMA Targets
ADC Development for CD19 Targets
ADC Development for CD22 Targets
ADC Development for CD30 Targets
ADC Development for CD33 Targets
ADC Development for CD79b Targets
ADC Development for c-MET Targets
ADC Development for EGFR Targets
ADC Development for FOLR1 Targets
ADC Development for HER2 Targets
ADC Development for Nectin-4 Targets
ADC Development for ROR1 Targets
ADC Development for TF Targets
ADC Development for TROP-2 Targets
ADC Development Platform
Antibody Fragment-Drug Conjugates (FDCs)
Bispecific Antibody-Drug Conjugates (BsADCs)
Degrader-Antibody Conjugates (DACs)
Nanobody-Drug Conjugates (NDCs)
Scaffold-Drug Conjugates (SDCs)
Products
ADCs Cytotoxin
Auristatins
Calicheamicins
Camptothecins
Daunorubicins/Doxorubicins
Duocarmycins
Maytansinoids
Piericidins
Pyrrolobenzodiazepines
Traditional Cytotoxic Agents
Others
ADCs Cytotoxin with Linkers
ADCs Linker
Cleavable Linkers
Non-cleavable Linkers
Antibody-Drug Conjugates (ADCs)
Resource
Frequently Asked Questions
News
Scientific Corner
Support Documents
Company
Contact Us
About Us
Careers
Inquiry
News
Home
Resource
News
News
Antibody-Drug Conjugates for Prostate Cancer
Current ADC Linker Chemistry
SPDB Linkers in Antibody-Drug Conjugates
Val-Cit Linkers in Antibody-Drug Conjugates
Microtubules: Definition, Structure, Function and Inhibitors
Site-Specific Conjugation for Antibody-Drug Conjugates (ADCs)
Camptothecin: Definition, Structure, and Mechanism of Action
Antibody-Drug Conjugates with Dual Payloads
Application of Click Chemistry in the Next Generation of Novel Antibody Drug Conjugation (ADCs)
Bispecific Antibodies and Bispecific Antibody ADCs
Bystander Effect of Antibody-Drug Conjugates (ADCs)
Challenges in ADC Neutralizing Anti-Drug Antibody (NAb) Detection
Characteristics of Ideal ADC Payloads
Clinical Pharmacology of Antibody-Drug Conjugates
Cytotoxic payloads in ADCs
Cytotoxins: Definition, Function, Classification and Mechanism of Action
Degrader-Antibody Conjugates (DAC): Novel PROTAC-ADC Conjugation Strategies
Disitamab Vedotin for the treatment of urothelial cancer was approved by the US FDA
Doxorubicin: Definition, Structure, Cardiotoxicity, Applications and Mechanism of Action
Drug Conjugates: Latest Research Progress
Drug-to-Antibody Ratio (DAR) Characterization of Antibody Drug Conjugation (ADCs)
Exatecan mesylate: a novel topoisomerase I inhibitor in ADC technolog
Kadcyla - The Most Commercially Successful ADC
Maytansine And Its Analogues
Nanobodies: Definition, Structure, Advantages and Applications
New medicine for lymphoma! Antibody-Drug Conjugate (ADC) loncastuximab tesirine (Lonca) applies for listing!
Overview of ADC Combination Therapies
Quantitative Analysis of ADC Components - Ligand Binding Assay (LBA) and LC-MS/MS
Review of ADC bioconjugation technology and research progress
Review of ADC linker and research progress
Review of ADC payload and research progress
Review of FDA-Approved ADC Drugs up to 2024
Studies have shown that thapsigargin has anti-COVID-19 virus (SARS-CoV-2) activity
TF-targeted antibody-drug conjugate (ADC) tisotumab vedotin shows strong efficacy and will be applied marketing
The development history of ADC drugs
Tivdak - The First FDA-Approved Tissue Factor-Targeted ADC
Tubulin Inhibitors - Highly Potential ADC Payloads
Two New Structures Resolved Unstable Maleimide Linkers in ADCs
What are Antibody Drug Conjugates?
What are Protein Toxins and Their Applications in ADCs
What are the Targets for ADC Therapy in Breast Cancer?
What is Bioconjugation? - Antibody Conjugation & Drug Conjugation
What is Calicheamicin?
What is Monomethyl Auristatin E (MMAE)?
What is Monomethyl Auristatin F (MMAF)?
What is Pyrrolobenzodiazepine (PBD)?
With rich potential, ADC drugs are expected to continue to broaden the scope of tumor treatment
Antibody-Drug Conjugates in Clinical Trials
ADC Transactions Flourish - UP to 10 Billion
Adcetris for Hodgkin's Lymphoma
Antibody-Drug Conjugate Immunotherapy
Antibody-Drug Conjugates for Brain Cancer
Antibody-Drug Conjugates for Lung Cancer
Biotinylation Reagents in Antibody-Drug Conjugates
Click Chemistry in Antibody Drug Conjugates
Disulfide Linkers in Antibody-Drug Conjugates
Elahere for Ovarian Cancer Treatment
Maleimide Linkers in Antibody-Drug Conjugates
PEG Linkers in Antibody-Drug Conjugates
Peptide Linkers in Antibody-Drug Conjugates
Trodelvy for Breast Cancer Treatment
*
Only for research. Not suitable for any diagnostic or therapeutic use.
Inquiry Basket
Loading ......
Delete selected
Go to checkout
